Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis
OBJECTIVESTo assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).DESIGNA coho...
Saved in:
Published in | Journal of medical economics Vol. 26; no. 1; pp. 1061 - 1071 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
31.12.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVESTo assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).DESIGNA cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a "watch and wait" state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature.RESULTSAt five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained.CONCLUSIONSTARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators. |
---|---|
AbstractList | OBJECTIVESTo assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and drug-eluting beads chemoembolization (DEE-TACE) for patients with unresectable early- to intermediate-stage hepatocellular carcinoma (HCC).DESIGNA cohort-based Markov model with a five-year time horizon was developed to evaluate the cost-effectiveness of the three embolization treatments. Upon entering the model, patients with HCC received either TARE or one of the two other embolization treatments. Patients remained in a "watch and wait" state for tumor downstaging that allowed them to move to health states such as liver transplant, resection, systemic therapies, or cure. Clinical input parameters were retrieved from the published literature, and where values could not be sourced, assumptions were made and validated by clinical experts. Health benefits were quantified using quality-adjusted life years (QALYs). Cost input parameters were obtained from various sources, including the Medicare Cost Report, IBM® Micromedex RED BOOK, and published literature.RESULTSAt five years, TARE was found to be cost-saving (saving $15,779 per person compared to cTACE) and produced 0.33 more QALYs per person than cTACE. TARE cost $13,696 more but produced 0.33 more QALYs than DEE-TACE, with an incremental cost-effectiveness ratio of $41,474 per QALY gained at five years. After accounting for parameter uncertainty, the likelihood of TARE being cost-effective was at least 90% against all comparators at a cost-effectiveness threshold of $100,000 per QALY gained.CONCLUSIONSTARE produces more QALYs than cTACE and DEE-TACE, with a high probability of being cost-effective against both comparators. |
Author | Patel, Mikin V. Anderson, Nicholas Mealing, Stuart Holmes, Hayden Bromilow, Tom Ahmed, Osman Davies, Heather Williams, Abimbola O. Baker, Hannah |
Author_xml | – sequence: 1 givenname: Mikin V. orcidid: 0000-0001-8715-2063 surname: Patel fullname: Patel, Mikin V. organization: Section of Interventional Radiology, Department of Radiology, University of Chicago Medicine, Chicago, IL, USA – sequence: 2 givenname: Heather orcidid: 0000-0003-1943-3765 surname: Davies fullname: Davies, Heather organization: York Health Economics Consortium, University of York, Heslington, UK – sequence: 3 givenname: Abimbola O. orcidid: 0000-0003-1982-8417 surname: Williams fullname: Williams, Abimbola O. organization: Boston Scientific, Marlborough, MA, USA – sequence: 4 givenname: Tom orcidid: 0000-0003-2494-5685 surname: Bromilow fullname: Bromilow, Tom organization: York Health Economics Consortium, University of York, Heslington, UK – sequence: 5 givenname: Hannah surname: Baker fullname: Baker, Hannah organization: York Health Economics Consortium, University of York, Heslington, UK – sequence: 6 givenname: Stuart orcidid: 0000-0002-2564-1440 surname: Mealing fullname: Mealing, Stuart organization: York Health Economics Consortium, University of York, Heslington, UK – sequence: 7 givenname: Hayden orcidid: 0000-0003-2559-061X surname: Holmes fullname: Holmes, Hayden organization: York Health Economics Consortium, University of York, Heslington, UK – sequence: 8 givenname: Nicholas surname: Anderson fullname: Anderson, Nicholas organization: Boston Scientific, Marlborough, MA, USA – sequence: 9 givenname: Osman surname: Ahmed fullname: Ahmed, Osman organization: Section of Interventional Radiology, Department of Radiology, University of Chicago Medicine, Chicago, IL, USA |
BookMark | eNpVkE1LxDAQhoMouOr-BCFHL12bNmlTbyJ-wYIHd8FbmaRTN5ImNckq-hf803ZRD85l5oWHF-Y5IvvOOyTklOULlsv8nJVVUzWNXBR5US6KgkvJ8z0yYw1nmSzrp_3pnphsBx2SeYwv-TRlyfKazcjXKoCLEBIGA5amDQYYDUZqHB0hGXQp0neTNnSDU_Yard1aCFRD0Mb5ASha82yURdr7QNO_OhyUt-Zz6vHuggJdP1LtY8qw71En84YOY6TgwH5EE0_IQQ824vx3H5P1zfXq6i5bPtzeX10uM11IljJddX1dKVYzJRrBFe8lQC94jV0ltRJCyqbTSmrZqYKriRTAOUjsoJaoVXlMzn56x-BftxhTO5i4ewwc-m1sCylqKcqqEhMqflAdfIwB-3YMZoDw0bK83flv__y3O__tr__yGx5cf0s |
Cites_doi | 10.1016/j.jhep.2021.11.018 10.1200/OP.20.00443 10.1016/s0140-6736(18)30207-1 10.1056/NEJMoa0708857 10.2147/jhc.S248314 10.3310/hta24480 10.1016/j.jval.2021.11.1351 10.1016/j.jval.2016.09.2397 10.1016/j.dld.2016.02.005 10.1016/j.jvir.2011.11.016 10.1002/hep.31318 10.1111/hpb.12300 10.2147/jhc.S335879 10.1148/radiol.2018171768 10.1148/radiol.211806 10.1002/hep.27135 10.1002/cncr.29855 10.1136/bmj.330.7491.597 10.1001/jama.2016.12195 10.2217/fon-2020-1004 10.1016/s2468-1253(20)30290-9 10.1016/j.jvir.2014.04.014 10.1056/NEJMp1405158 10.5009/gnl.2010.4.S1.S113 10.1200/op.21.00227 10.1038/bjc.2014.199 10.1053/j.gastro.2016.08.029 10.1007/s11136-020-02650-y 10.15761/gos.1000171 10.1007/s11605-008-0652-2 10.1111/j.1600-6143.2009.02695.x 10.1002/hep.31819 10.1016/j.ejso.2020.08.027 |
ContentType | Journal Article |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1080/13696998.2023.2248840 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1941-837X |
EndPage | 1071 |
ExternalDocumentID | 10_1080_13696998_2023_2248840 |
GroupedDBID | --- 00X 03L 0YH 4.4 53G 5GY AALUX AAWTL AAYXX ABLKL ABUPF ACENM ACGFS ADCVX ADRBQ AENEX AEOZL AIJEM ALMA_UNASSIGNED_HOLDINGS BABNJ BLEHA BOHLJ CCCUG CITATION DKSSO EBS EMOBN F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- OK1 TDBHL TFDNU TFL TFW V1S ~1N 7X8 |
ID | FETCH-LOGICAL-c281t-c6df76b171b5954b4f8aaf547ed68cb55889dcb8c8db24b6b15a44a8eda78ecb3 |
ISSN | 1369-6998 |
IngestDate | Sat Aug 17 02:37:08 EDT 2024 Fri Dec 06 01:27:16 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c281t-c6df76b171b5954b4f8aaf547ed68cb55889dcb8c8db24b6b15a44a8eda78ecb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2559-061X 0000-0001-8715-2063 0000-0003-1943-3765 0000-0003-1982-8417 0000-0003-2494-5685 0000-0002-2564-1440 |
OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2248840?needAccess=true&role=button |
PQID | 2857853665 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2857853665 crossref_primary_10_1080_13696998_2023_2248840 |
PublicationCentury | 2000 |
PublicationDate | 2023-12-31 |
PublicationDateYYYYMMDD | 2023-12-31 |
PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-31 day: 31 |
PublicationDecade | 2020 |
PublicationTitle | Journal of medical economics |
PublicationYear | 2023 |
References | e_1_3_9_5_1 e_1_3_9_32_1 e_1_3_9_4_1 e_1_3_9_10_1 e_1_3_9_7_1 e_1_3_9_6_1 American Association for Cancer Research (e_1_3_9_40_1) 2022 e_1_3_9_13_1 e_1_3_9_36_1 e_1_3_9_14_1 e_1_3_9_35_1 e_1_3_9_3_1 e_1_3_9_11_1 e_1_3_9_34_1 e_1_3_9_2_1 e_1_3_9_12_1 e_1_3_9_33_1 e_1_3_9_17_1 e_1_3_9_18_1 e_1_3_9_39_1 e_1_3_9_15_1 e_1_3_9_38_1 e_1_3_9_16_1 e_1_3_9_37_1 e_1_3_9_9_1 e_1_3_9_8_1 e_1_3_9_19_1 e_1_3_9_20_1 e_1_3_9_43_1 e_1_3_9_21_1 e_1_3_9_42_1 e_1_3_9_41_1 e_1_3_9_24_1 Bentley TS (e_1_3_9_30_1) 2020 e_1_3_9_47_1 e_1_3_9_25_1 e_1_3_9_46_1 e_1_3_9_22_1 e_1_3_9_45_1 e_1_3_9_44_1 National Institute for Health and Care Excellence (e_1_3_9_23_1) 2018 e_1_3_9_28_1 e_1_3_9_29_1 e_1_3_9_26_1 e_1_3_9_27_1 e_1_3_9_48_1 Arias E. United States Life (e_1_3_9_31_1) 2019; 68 |
References_xml | – ident: e_1_3_9_35_1 – ident: e_1_3_9_4_1 doi: 10.1016/j.jhep.2021.11.018 – ident: e_1_3_9_38_1 – ident: e_1_3_9_32_1 – ident: e_1_3_9_43_1 doi: 10.1200/OP.20.00443 – ident: e_1_3_9_46_1 doi: 10.1016/s0140-6736(18)30207-1 – ident: e_1_3_9_28_1 doi: 10.1056/NEJMoa0708857 – ident: e_1_3_9_17_1 doi: 10.2147/jhc.S248314 – ident: e_1_3_9_36_1 doi: 10.3310/hta24480 – volume: 68 start-page: 1 issue: 7 year: 2019 ident: e_1_3_9_31_1 article-title: Tables, 2017. National vital statistics reports: from the centers for disease control and prevention, national center for health statistics publication-title: Natl Vital Stat Sys contributor: fullname: Arias E. United States Life – ident: e_1_3_9_45_1 doi: 10.1016/j.jval.2021.11.1351 – ident: e_1_3_9_42_1 doi: 10.1016/j.jval.2016.09.2397 – ident: e_1_3_9_20_1 doi: 10.1016/j.dld.2016.02.005 – ident: e_1_3_9_44_1 doi: 10.1016/j.jvir.2011.11.016 – ident: e_1_3_9_33_1 – ident: e_1_3_9_12_1 doi: 10.1002/hep.31318 – ident: e_1_3_9_37_1 – ident: e_1_3_9_22_1 doi: 10.1111/hpb.12300 – ident: e_1_3_9_7_1 doi: 10.2147/jhc.S335879 – ident: e_1_3_9_19_1 doi: 10.1148/radiol.2018171768 – ident: e_1_3_9_9_1 doi: 10.1148/radiol.211806 – volume-title: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089] year: 2018 ident: e_1_3_9_23_1 contributor: fullname: National Institute for Health and Care Excellence – ident: e_1_3_9_24_1 doi: 10.1002/hep.27135 – ident: e_1_3_9_2_1 doi: 10.1002/cncr.29855 – ident: e_1_3_9_14_1 doi: 10.1136/bmj.330.7491.597 – ident: e_1_3_9_18_1 doi: 10.1001/jama.2016.12195 – ident: e_1_3_9_41_1 doi: 10.2217/fon-2020-1004 – ident: e_1_3_9_47_1 doi: 10.1016/s2468-1253(20)30290-9 – ident: e_1_3_9_15_1 doi: 10.1016/j.jvir.2014.04.014 – volume-title: 2020 U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues year: 2020 ident: e_1_3_9_30_1 contributor: fullname: Bentley TS – ident: e_1_3_9_39_1 doi: 10.1056/NEJMp1405158 – ident: e_1_3_9_48_1 doi: 10.5009/gnl.2010.4.S1.S113 – ident: e_1_3_9_3_1 doi: 10.1200/op.21.00227 – ident: e_1_3_9_21_1 doi: 10.1038/bjc.2014.199 – ident: e_1_3_9_25_1 – ident: e_1_3_9_8_1 doi: 10.1053/j.gastro.2016.08.029 – ident: e_1_3_9_26_1 doi: 10.1007/s11136-020-02650-y – ident: e_1_3_9_34_1 – ident: e_1_3_9_6_1 – ident: e_1_3_9_5_1 doi: 10.15761/gos.1000171 – ident: e_1_3_9_29_1 doi: 10.1007/s11605-008-0652-2 – ident: e_1_3_9_11_1 doi: 10.1111/j.1600-6143.2009.02695.x – ident: e_1_3_9_10_1 doi: 10.1002/hep.31819 – start-page: 609 volume-title: Clin Cancer Res year: 2022 ident: e_1_3_9_40_1 contributor: fullname: American Association for Cancer Research – ident: e_1_3_9_16_1 – ident: e_1_3_9_13_1 doi: 10.1016/j.ejso.2020.08.027 – ident: e_1_3_9_27_1 |
SSID | ssj0000331071 |
Score | 2.375127 |
Snippet | OBJECTIVESTo assess the cost-effectiveness of transarterial radioembolization (TARE) versus conventional transarterial chemoembolization (cTACE) and... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
StartPage | 1061 |
Title | Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis |
URI | https://search.proquest.com/docview/2857853665 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBXb9FIooZ80aVNU6G3x1h-yVs4thISlpEkhNmxPRpJlumTXLo330r_QP9CfmxnLcm26hbQXY4wsG83zaDR-b0TIe1WyiKuo9CCYlx4rfe0lABSvKCR8H4FORMsm_HTJFxn7uIyXk8mvAWtp26iZ_rFTV_I_VoVrYFdUyf6DZftO4QKcg33hCBaG4_1s3G72jaTMVv3RSqlWxjLDbb3UTrz2FSadpsYkfcs61biBUFVv5LQlJKN4qmUbjrozG1WvO5WmlURn11Nd3zae5YA4Nym7siZ_CXM33Z8g0ymg-xj-M0S5a8vcv4EX7sm2yLK3vmthw9NdqaETtcLXk9OrQT5hs1rbP1WpHWuXzQgjVzMRJyPrgRMWeLBqXg5dtBXVj6Bo_S0uaAdzN6xlg53zgiVSBrh5IawvZ_jkGQQvQthaUeM63JdX-Xl2cZGnZ8v0AXmIJRZxVwb_y6LP3vlRhM9ykjDhf9jZ9zjYGc_1bQCTPiH7nUnoiYXRUzIx1TPy2KZtqVWjPSc_R5CiPaToqqIOUhQhRceQoj2kqIMUBUjREaToEFLHVNLsmv4JKOoA9YJk52fp6cLr9uvwdCiCxtO8KOdcBfNAxUnMFCuFlGXM5qbgQqs4FiIptBJaFCpkClrGkjEpTCHnwmgVvSR7VV2ZV4RiJT-fY24gKlgZQ7tClHBXwKVSMgoPyMwNbP7NlmXJg67arbNEjpbIO0sckHdu-HNwoDg6sjL19jYPBdZ7ijiPD-_R5jV59Bu2b8he831rjiAsbdTbFiF3TuiWZw |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Taylor & Francis |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Transarterial+therapies+in+patients+with+hepatocellular+carcinoma+eligible+for+transarterial+embolization%3A+a+US+cost-effectiveness+analysis&rft.jtitle=Journal+of+medical+economics&rft.au=Patel%2C+Mikin+V&rft.au=Davies%2C+Heather&rft.au=Williams%2C+Abimbola+O&rft.au=Bromilow%2C+Tom&rft.date=2023-12-31&rft.eissn=1941-837X&rft.volume=26&rft.issue=1&rft.spage=1061&rft.epage=1071&rft_id=info:doi/10.1080%2F13696998.2023.2248840&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1369-6998&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1369-6998&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1369-6998&client=summon |